Abstract: Mutated K-RAS can been observed among 15-30% NSCLC patients,the mutations of K-RAS and EGFR are mutually exclusive,K-RAS mutations have poor sensitivity to EGFR-TKIs,The response of C-225 is not restricted to mutated K-RAS , NSCLC patients with K-RAS mutations are associated with unfavorable prognosis.A number of different approaches such as Ftase inhibitors,RAF inhibitors,MEK inhibitors aimed at abrogating K-RAS activity to improve clinical response have been explored in clinical trials.

Key words: K-RAS, non-small cell cancer